Q32 Bio (QTTB) Gains from Sales and Divestitures (2022 - 2026)

Q32 Bio's Gains from Sales and Divestitures history runs 4 years deep, the most recent figure standing at $104737.0 for Q1 2026.

• In Q1 2026, Gains from Sales and Divestitures changed N/A year-over-year to $104737.0; the TTM figure through Mar 2026 stood at $104737.0 (changed N/A YoY), while the FY2025 annual figure was $106737.0, changed N/A from the prior year.
• Gains from Sales and Divestitures was $104737.0 for Q1 2026 at Q32 Bio, down from $106737.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $373519.0 in Q4 2023 to a low of $87140.0 in Q1 2022.
• Historically, Gains from Sales and Divestitures has averaged $158787.0 across 4 years, with a median of $106737.0 in 2025.
• Biggest YoY gain for Gains from Sales and Divestitures was 249.44% in 2023; the steepest drop was 123.23% in 2023.
• A 4-year view of Gains from Sales and Divestitures shows it stood at $106890.0 in 2022, then soared by 249.44% to $373519.0 in 2023, then tumbled by 71.42% to $106737.0 in 2025, then decreased by 1.87% to $104737.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $104737.0 (Q1 2026), $106737.0 (Q4 2025), and $106737.0 (Q3 2025), per Business Quant data.